Open AccessBrief Report: Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection
Author(s) -
Timothy Archampong,
Oluwayemisi Ojewale,
Kristi Bears,
Yiqing Chen,
Margaret Lartey,
Kwamena W.C. Sagoe,
Adjoa Obo-Akwa,
Yan Gong,
Taimour Langaee,
Awewura Kwara
Publication year - 2019
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002136
Subject(s) - lamivudine , hepatitis b virus , virology , medicine , hepatitis b , genotype , single nucleotide polymorphism , coinfection , efavirenz , viral load , immunology , biology , genetics , antiretroviral therapy , virus , gene
Incomplete hepatitis B virus (HBV) suppression during antiretroviral therapy (ART) in HIV and HBV coinfected patients is common, but underlying factors are not fully elucidated. We hypothesize that genetic factors that influence nucleoside analog pharmacokinetics will affect HBV treatment response.